Medifast, Inc. (MED)

Medifast's stock price has declined significantly over the past year and six months. The stock fell by 29.50% over the last 12 months and approximately 27.7% in the past six months, trading at $9.88 as of March 30, 2026. In Q4 2025, Medifast reported a net loss of $18.1 million, with revenue decreasing by 36.9%. The adoption of GLP-1 medications has contributed to a decrease in active OPTAVIA Coaches and reduced productivity per coach. Medifast announced a cooperation agreement with Steamboat Capital. OPTAVIA is now available for HSA and FSA reimbursement. A planned leadership transition was announced in January 2026.

Demand for weight management products and programs is typically seasonal. The fourth quarter is impacted by clients being less predisposed to initiate a weight loss or management program during the holiday season, leading to fewer sales.

Medifast, Inc. is a health and wellness company known for its OPTAVIA program, which offers a habit-based and coach-guided lifestyle solution. The company operates in the Consumer Cyclical sector, focusing on weight loss services. Medifast provides OPTAVIA-branded Fuelings, portion-controlled meal replacements, and the OPTAVIA ACTIVE line of amino acid supplements and protein powders. Medifast has collaborated with LifeMD, Inc. to offer OPTAVIA customers access to clinicians and medications, including GLP-1s.

Medifast's primary market is the United States. The company has expanded internationally through subsidiaries in Hong Kong, Singapore and Shanghai, indicating a presence in Asia. Medifast also serves customers in Canada.

Historically, Medifast has received positive recognition, including being ranked number 1 on Forbes magazine's list of "America's 100 Best Small Companies" in October 2010 and named one of Forbes's 100 Most Trustworthy Companies in America in 2016 and 2017. In the past year, Medifast's brand reputation has likely been influenced by the challenges it faces in the evolving weight loss market. The company is actively working to transform its business model to focus on optimal metabolic health and is introducing new product lines to address these evolving market demands. Medifast's collaboration with LifeMD to integrate GLP-1 medications into its offerings also reflects an adaptation to changing consumer needs.

Medifast, Inc. has significant institutional ownership. As of March 27, 2026, 115 institutional owners and shareholders held 8,064,963 shares. Major institutional owners include BlackRock, Inc., Renaissance Technologies Llc, Charles Schwab Investment Management Inc, and Vanguard Group Inc. Institutional ownership accounts for approximately 66.3% of the company, with individuals holding about 3.3%.